Sugi Predict

Sugi Predict / Compounds / SCHEMBL497738

SCHEMBL497738

SCHEMBL497738

C[C@]12CCCCC1CC[C@@H]1[C@H]2CC[C@@]2(C)[C@H]1CCC2(O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.54
▸ ATP1A1 P05023 1/20 0.49
▸ ATP1B1 P05026 1/20 0.49
▸ ATP1A3 P13637 1/20 0.49
▸ ATP1B2 P14415 1/20 0.49
▸ ATP1A2 P50993 1/20 0.49
▸ ATP1B3 P54709 1/20 0.49
▸ FXYD2 P54710 1/20 0.49
▸ ATP1A4 Q13733 1/20 0.49
▸ SHBG P04278 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ AKR1B10 O60218 1/20 0.46
▸ AKR1B1 P15121 1/20 0.46
▸ EFNA1 P20827 1/20 0.46
▸ EPHA2 P29317 1/20 0.46
▸ PSEN1 P49768 1/20 0.46
▸ PSEN2 P49810 1/20 0.46
▸ GPBAR1 Q8TDU6 1/20 0.46
▸ APH1B Q8WW43 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21807731 1.00 CYP19A1 (0.54) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL10402805 0.88 SHBG (0.60) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL10402803 0.88 SHBG (0.60) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL10403839 0.85 CYP19A1 (0.51) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL3636518 0.85 CYP19A1 (0.51) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL10402806 0.85 CYP19A1 (0.51) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL4620111 0.84 CYP19A1 (0.56) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL4620105 0.84 CYP19A1 (0.56) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL23640542 0.82 ATP1A1 (0.51) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL3363326 0.82 CYP19A1 (0.49) CYP19A1ATP1A1ATP1B1ATP1A3ATP1B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014107794-A1 FORMULATIONS AND METHODS FOR THEIR USE IN TREATMENT OF NEUROPATHOLOGY AND NEURODEGENERATION AS A RESULT OF TRAUMATIC INJURY SAPNA LIFE SCIENCES CORP. (CA) 2014-07-17 — — WO claimed
EP-1539183-A4 THERAPEUTIC TREATMENT METHODS HOLLIS EDEN PHARMACEUTICALS (US) 2007-04-25 — — EP claimed
EP-1539183-A1 THERAPEUTIC TREATMENT METHODS Hollis-Eden Pharmaceuticals Inc. (US) 2005-06-15 — — EP claimed
WO-2004019953-A1 THERAPEUTIC TREATMENT METHODS HOLLIS-EDEN PHARMACEUTICALS, INC. (US) 2004-03-11 — — WO claimed
US-20210346385-A1 TASTE-MASKED DOSAGE FORMS DEEP OCEAN CAPITAL MANAGEMENT LP 2021-11-11 — — US disclosed
WO-2020061584-A1 TASTE-MASKED DOSAGE FORMS MSB HOLDINGS, INC. (US) 2020-03-26 — — WO disclosed
US-9102702-B2 Steroids having 7-oxygen and 17-heteroaryl substitution-2 NEURMEDIX INC. (US) 2015-08-11 — — US disclosed
US-20140018336-A1 Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 Harbor Therapeutics, Inc. (US) 2014-01-16 — — US disclosed
EP-2471536-A1 STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS Harbor BioSciences, Inc. (US) 2012-07-04 — — EP disclosed
US-8106036-B2 Pharmaceutical compositions-4 HARBOR BIOSCIENCES, INC. (US) 2012-01-31 — — US disclosed
US-20100222313-A1 PHARMACEUTICAL COMPOSITIONS-4 BIOVIE INC. 2010-09-02 — — US disclosed
US-7723532-B2 Pharmaceutical compositions 3 HARBOR BIOSCIENCES, INC. (US) 2010-05-25 — — US disclosed
EP-1372664-A1 USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES Hollis-Eden Pharmaceuticals Inc. (US) 2004-01-02 — — EP disclosed
US-20030083231-A1 Blood cell deficiency treatment method BIOVIE INC. 2003-05-01 — — US disclosed
WO-2002069977-A1 USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES HOLLIS-EDEN PHARMACEUTICALS, INC. (US) 2002-09-12 — — WO disclosed
EP-1163256-A1 HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE Hollis-Eden Pharmaceuticals Inc. (US) 2001-12-19 — — EP disclosed
WO-2000056757-A1 IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE HOLLIS-EDEN PHARMACEUTICALS, INC. (US) 2000-09-28 — — WO disclosed
US-6090957-A Process for preparing neuromuscular blocking agents and intermediates useful therefor POLI INDUSTRIA CHIMICA S.P.A. (IT) 2000-07-18 — — US disclosed
US-5175144-A Administering agent which suppresses endogenous production of glucocorticoids THE JOHNS HOPKINS UNIVERSITY (US) 1992-12-29 — — US disclosed
EP-0496134-A1 Use of 2 beta, 16 beta-diamino-3 alpha, 17-dihydroxy androstane derivatives for the treatment of arrhythmic disorders Akzo Nobel N.V. (NL) 1992-07-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083231-A1 Blood cell deficiency treatment method THPO, HPGDS, MPL CYP19A1 21/4885ATP1A1 4428/4885ATP1B1 4519/4885
US-20140018336-A1 Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 HSD3B1, HSD3B2, HSD17B13 CYP19A1 33/4885ATP1A1 3327/4885ATP1B1 3275/4885
US-20100222313-A1 PHARMACEUTICAL COMPOSITIONS-4 HSD3B1, HSD3B2, HSD17B7 CYP19A1 33/4885ATP1A1 2163/4885ATP1B1 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.